| Michael Joseph Zagarella, MA | |
|
400 W King St, Martinsburg, WV 25401-3204 | |
| (304) 267-8220 | |
| Not Available |
| Full Name | Michael Joseph Zagarella |
|---|---|
| Gender | Male |
| Speciality | Qualified Audiologist |
| Experience | 18 Years |
| Location | 400 W King St, Martinsburg, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386633196 | NPI | - | NPPES |
| 0160831000 | Medicaid | WV | |
| 0160831001 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | A-0025 (West Virginia) | Primary |
| Provider Name | Audiology Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518093533 PECOS PAC ID: 1456337419 Enrollment ID: O20040629000795 |
News Archive
Over the past thirty years, physical activity among children has declined markedly. The public health implications of this decline include a growing prevalence of obesity and chronic diseases such as diabetes and hypertension. A new issue of Monographs of the Society for Research in Child Development expands the focus to ask whether physical activity is also related to children's brain and cognitive development and achievement in school.
In a post on the PATH blog, Rachel Wilson, senior director for policy and advocacy at PATH, examines the consequences of budget negotiations and "what enacting billions of dollars in automatic spending cuts could mean for people living in poverty around the world.
A team of researchers led by Alex Toker of the Ludwig Center at Harvard has discovered a metabolic weakness in triple-negative breast cancer cells that may be exploited to quell their resistance to chemotherapy.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Joseph Zagarella, MA 400 W King St, Martinsburg, WV 25401-3204 Ph: (304) 267-8220 | Michael Joseph Zagarella, MA 400 W King St, Martinsburg, WV 25401-3204 Ph: (304) 267-8220 |
News Archive
Over the past thirty years, physical activity among children has declined markedly. The public health implications of this decline include a growing prevalence of obesity and chronic diseases such as diabetes and hypertension. A new issue of Monographs of the Society for Research in Child Development expands the focus to ask whether physical activity is also related to children's brain and cognitive development and achievement in school.
In a post on the PATH blog, Rachel Wilson, senior director for policy and advocacy at PATH, examines the consequences of budget negotiations and "what enacting billions of dollars in automatic spending cuts could mean for people living in poverty around the world.
A team of researchers led by Alex Toker of the Ludwig Center at Harvard has discovered a metabolic weakness in triple-negative breast cancer cells that may be exploited to quell their resistance to chemotherapy.
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.
A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.
› Verified 8 days ago
Dr. W. Scott Wood Iii, PH.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 510 Butler Ave, Division Of Rehabilitation Services (117), Martinsburg, WV 25401 Phone: 304-263-0811 Fax: 304-262-4842 | |
Lindsay Beth Bruce, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2000 Foundation Way, Suite 3200, Martinsburg, WV 25401 Phone: 304-262-9400 Fax: 304-262-9407 | |
Caroline Doepping, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 510 Butler Ave, Audiology, Martinsburg, WV 25405 Phone: 304-263-0811 | |
Dr. Christopher Carlyle France, AU.D., CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 510 Butler Ave, Martinsburg, WV 25405 Phone: 304-263-0811 | |
Mrs. Julie Beth Shallis, M.S., CCC/A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 510 Butler Ave, Martinsburg, WV 25401 Phone: 304-263-0811 | |
University Healthcare Physicians, Inc. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2000 Foundation Way, Ste 3200, Martinsburg, WV 25401 Phone: 304-262-9400 Fax: 304-262-9407 |